JAK2 DNA Analysis - V617F Mutation
Definition
A nucleotide change in exon 14 of the JAK2 gene causes a valine to phenylalanine (V617F) substitution in the JH2 pseudokinase domain. This change constitutively activates the JAK/STAT signaling pathway independent of erythropoietin. It is detected in approximately 90 to 98% of polycythemia vera (PV) cases and in 50 to 60% of essential thrombocythemia and primary myelofibrosis cases.
Method
DNA analysis
Accepted sample types
Blood (EDTA), bone marrow (EDTA)
Description
Monitoring response to drug treatment and relapse in various cancer types. Essential Thrombocythemia (ET), Hypereosinophilic Syndrome (HES), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndromes (MDS), Myelofibrosis with Myeloid Metaplasia, Neutrophilic Leukemia (NL), Polycythemia Vera (PV), Mast Cell Leukemia, Mastocytosis.
Inheritance
This is somatic, a driver mutation acquired in the hematopoietic stem cell; it is not inherited.